Top Markets
#1 MowCat MowCat +48.93%
#2 Velvet Velvet +23.57%
#3 Derive Derive +21.01%
#4 Quack AI Quack AI +20.19%
#5 Bermuda Shorts Bermuda Shorts +15.80%
#6 MarsCoin MarsCoin +15.17%
#7 Geodnet Geodnet +14.36%
#8 Audiera Audiera +13.55%
#9 Cross Cross +13.10%
#10 aPriori aPriori +12.66%
Coin of the day
MowCat MowCat
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

MyMD Pharmaceuticals, Inc.

MYMD
Clasificación en acciones #35400
MyMD Pharmaceuticals, Inc. is a pharmaceutical firm currently in the clinical... MyMD Pharmaceuticals, Inc. is a pharmaceutical firm currently in the clinical development stage, focused on devising diverse therapeutic strategies that target the underlying origins of various illnesses. One of its key initiatives is the development of MYMD-1, a drug platform centered on a small molecule presently undergoing clinical trials. This molecule works by regulating the immune system to suppress TNF-alpha, a major contributor to chronic inflammation, along with other pro-inflammatory cell-signaling proteins. MYMD-1 is being explored for its potential to delay aging, extend lifespan, manage autoimmune conditions, and treat depression linked to COVID-19. Furthermore, the company is advancing Supera-CBD, a synthetic version of cannabidiol, which aims to address chronic pain, addiction, and epilepsy. MyMD Pharmaceuticals was established in 2014 and its corporate headquarters are situated in Baltimore, Maryland.
Precio por acción
$1.85
Última sincronización: 2024-08-19
Capitalización bursátil
$3.96M
Cambio (1 día)
2.78%
Cambio (1 año)
0.00%
País
US
Comercio MyMD Pharmaceuticals, Inc. (MYMD)

Categoría

Healthcare
Ingresos de MyMD Pharmaceuticals, Inc. (MYMD)
Ingresos en Aug 2026 TTM: 0
Según los últimos informes financieros de MyMD Pharmaceuticals, Inc., los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de MyMD Pharmaceuticals, Inc. desde 2026 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
Not enough data for the provided dates.
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE